KRAS and ovarian carcinoma: Pathway analysis of the top 100 significantly downregulated genes (determined by p-value) identified significant enrichment in cell cycle progression, quiescence, metastasis, differentiation, and KRAS-signaling (Fig. 4f)55–57, further suggesting SE60 drives critical gene expression programs in ovarian cancer.